Major Pan-European report highlights stark inequalities in cancer treatment throughout Europe
A report by the Karolinska Institutet, in conjunction with the Stockholm School of Economics, exposes stark inequalities in patient access to cancer treatment across Europe and urges action by decision makers to redress these inequalities.
The report, entitled ‘A pan-European comparison regarding patient access to cancer drugs’, found that despite the proven benefits of new innovative treatments options, patients across Europe do not have equality of access to these cancer drugs and the speed at which patients can benefit from them depends to a great extent upon the country in which they live.
Nineteen countries, representing almost 75% of Europe’s population, were included in the report. Austria, Spain, and Switzerland are shown to be the leaders in terms of early adoption and availability of new cancer drugs whereas other countries, such as the UK, Czech Republic, Hungary Norway, and Poland lag behind.
“Patients have to wait too long to obtain the benefits of newer therapies and the biggest hurdle to the uptake of new drugs is the proactive allocation of financial resources and budget in the health care systems by policy and decision makers”, says Dr. Nils Wilking of the Karolinska Institutet.
Drs Wilking and Jönsson point out that the total healthcare cost for cancer in countries included in this report is an estimated 120 euros per citizen – only 5% of total healthcare expenditure. The cost of cancer drugs per capita ranges from 7 euros to 16 euros per citizen in Europe. Costs associated with inpatient hospital care costs dominate the direct costs of cancer in Europe, accounting for 60% to 94% of all costs and less than 10% is spent on drugs. The share of health care costs for cancer is much less than the share of burden of the disease.
“A superior approach for cancer patients in Europe would be to take a broader perspective on the benefits and costs these drugs bring to patients and society, and introduce a more rational system of allocation of resources to the healthcare system,” explained Dr. Bengt Jönsson of the Stockholm School of Economics. “It is worth emphasising that new treatments are usually targeted to specifically identifiable populations” ‘he continued. Dr Jönsson also added “There are examples of best practice in some countries which try to expedite patient access to innovative therapies - these should be assessed on their applicability for more countries in Europe.”
The report also argues that while new therapies generally increase health expenditure, the value they bring to patients in terms of survival and treating their cancer must be recognized. Research undertaken in the U.S. by Dr. Frank Lichtenberg of Columbia University suggests that access to more and newer cancer drugs improves survival rates.
For further information, please contact:
Nils Wilking, mobile +46 73 625 17 19, e-mail: firstname.lastname@example.org
Bengt Jönsson, mobile +46 70 847 03 63, e-mail Bengt.Jonsson@hhs.se
Sabina Bossi | alfa
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.
Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...
Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.
Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...
Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.
As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...
Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.
With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...
Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine
Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...